1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. DEMAND FROM GOVERNMENTS FOR DIAGNOSING COVID-19 POSITIVE PATIENTS
3.2.2. RISE IN DEMAND FOR NON-INVASIVE DIAGNOSIS
3.2.3. GROWTH IN THE NUMBER OF DISEASES
3.2.4. FUNDING FOR RESEARCH AND DEVELOPMENT
3.2.5. TECHNOLOGICAL ADVANCEMENTS IN THE MARKET
3.3. KEY RESTRAINTS
3.3.1. HIGH CAPITAL REQUIREMENT
3.3.2. LACK OF HIGH COMPLEXITY TESTING CENTERS

4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER'S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. REGULATORY FRAMEWORK

5. MARKET BY TECHNOLOGY
5.1. POLYMERASE CHAIN REACTION
5.1.1. REAL TIME PCR
5.1.2. DIGITAL PCR
5.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
5.3. OTHER

6. MARKET BY PRODUCT
6.1. ASSAYS
6.2. INSTRUMENTS
6.3. SOFTWARE

7. MARKET BY APPLICATION
7.1. INFECTIOUS DISEASE
7.1.1. RESPIRATORY
7.1.2. HOSPITAL ACQUIRED INFECTIONS
7.1.3. SEXUALLY TRANSMITTED INFECTIONS
7.1.4. GASTRO INTESTINAL INFECTIONS
7.2. ONCOLOGY
7.3. PRENATAL
7.4. OTHERS

8. MARKET BY END-USER
8.1. HOSPITALS
8.2. CLINICS
8.3. DIAGNOSTICS CENTRES
8.4. OTHERS

9. GEOGRAPHICAL ANALYSIS
9.1. EUROPE
9.1.1. UNITED KINGDOM
9.1.2. GERMANY
9.1.3. FRANCE
9.1.4. ITALY
9.1.5. RUSSIA
9.1.6. BELGIUM
9.1.7. POLAND
9.1.8. REST OF EUROPE

10. COMPANY PROFILES
10.1. ABBOTT LABORATORIES
10.2. ABACUS DIAGNOSTICA
10.3. BIOMÉRIEUX SA
10.4. BIOCARTIS NV
10.5. DANAHER CORPORATION
10.6. DIASORIN SPA
10.7. BIO-RAD
10.8. F HOFFMANN-LA ROCHE AG
10.9. LUMINEX CORPORATION
10.10. HOLOGIC INC
10.11. MESA BIOTECH
10.12. SPARTAN BIOSCIENCES INC
10.13. QUANTUMDX GROUP LTD
10.14. QUIDEL CORPORATION
10.15. QIAGEN NV